The UK has agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal that will cost an estimated additional £3bn a year.
The transatlantic agreement will also see the health service in England, which currently spends £14.4bn a year on innovative therapies, double the percentage of GDP it allocates to buying such products, from 0.3% to 0.6% over the next decade.
